RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RNXT RenovoRx Inc

Pre-Mkt 02-06 07:35:18 EST

0.9509

-0.0136

-1.41%

盘前1.02

+0.0691+7.27%

05:33 EST

High1.01	Low0.9200	Vol200.79K
Open0.9200	D1 Closing0.9645	Amplitude9.33%
Mkt Cap34.85M	Tradable Cap28.62M	Total Shares36.65M
T/O198.19K	T/O Rate0.67%	Tradable Shares30.09M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RNXT","market":"US","secType":"STK","nameCN":"RenovoRx Inc","latestPrice":0.9509,"timestamp":1770325200000,"preClose":0.9645,"halted":0,"volume":200793,"hourTrading":{"tag":"盘前","latestPrice":1.02,"preClose":0.9509,"latestTime":"05:33 EST","volume":1,"amount":1.02,"timestamp":1770374014573,"change":0.0691,"changeRate":0.072668,"amplitude":0},"delay":0,"changeRate":-0.014100570243649618,"floatShares":30093240,"shares":36649916,"eps":-0.3554,"marketStatus":"Pre-Mkt","change":-0.0136,"latestTime":"02-06 07:35:18 EST","open":0.92,"high":1.01,"low":0.92,"amount":198194.34502572,"amplitude":0.093313,"askPrice":1.04,"askSize":118,"bidPrice":0.8688,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.3554,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1770388200000},"marketStatusCode":1,"adr":0,"listingDate":1629950400000,"exchange":"NASDAQ","adjPreClose":0.9509,"preHourTrading":{"tag":"盘前","latestPrice":1.02,"preClose":0.9509,"latestTime":"05:33 EST","volume":1,"amount":1.02,"timestamp":1770374014573,"change":0.0691,"changeRate":0.072668,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":0.9509,"preClose":0.9509,"latestTime":"19:34 EST","volume":71,"amount":68.4145,"timestamp":1770338086369,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.809967955751513},"requestUrl":"/m/hq/s/RNXT","defaultTab":"news","newsList":[{"id":"2609565305","title":"RenovoRx appoints Voll as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2609565305","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609565305?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:40","pubTimestamp":1770298828,"startTime":"0","endTime":"0","summary":"RenovoRx (RNXT) announces the appointment of Mark Voll as the Company’s Chief Financial Officer, effective February 1, 2026. Voll brings more than ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/renovorx-appoints-voll-as-chief-financial-officer-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/renovorx-appoints-voll-as-chief-financial-officer-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNXT","BK4139","BK4539"],"gpt_icon":0},{"id":"2609303121","title":"RenovoRx Names Mark Voll Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2609303121","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609303121?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:30","pubTimestamp":1770298221,"startTime":"0","endTime":"0","summary":"RenovoRx Inc. has appointed Mark Voll as Chief Financial Officer, effective February 1, 2026. Ronald B. Kocak will remain with the finance team during a transition period, and Lilly Huang has joined as Executive Director of Finance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via GlobeNewswire  on February 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDLD6BtS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014005.SGD","BK4139","IE00B64PRP62.GBP","BK4112","NDAQ","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD","IE00BGHQF748.EUR","RNXT","BK4585","SG9999014021.USD","BK4588","BK4539","SG9999014013.SGD","SG9999014039.USD","LU2210149790.SGD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2609530342","title":"Press Release: RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2609530342","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609530342?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:30","pubTimestamp":1770298200,"startTime":"0","endTime":"0","summary":"MOUNTAIN VIEW, Calif., Feb. 05, 2026  -- RenovoRx, Inc.  , a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath , a patented, FDA-cleared drug-delivery device, is pleased to announce the appointment of Mark Voll as the Company's Chief Financial Officer, effective February 1, 2026.Mr. Voll brings more than three decades of financial leadership experience to RenovoRx, with a strong track record for guiding high-growth public companies through periods of commercial buildout and strategic development. He has served as Chief Financial Officer for multiple publicly traded technology companies where he successfully led corporate initiatives that scaled early growth to full commercial development.RenovoRx's plans for Mr. Voll include a forward-facing role in stockholder communications as well as leveraging his extensive experience in budgeting, strategic planning, and finance. His expertise in managing operations will be instrumental as Renov","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IAG","BK4139","R","LU0345780521.USD","BK4588","BK4099","BK4539","BK4232","BK4555","RNXT","TM","BK4017","LU0345780281.USD","BK4585","BK4022","BK4604","03160"],"gpt_icon":0},{"id":"2608736296","title":"RenovoRx Unveils Clinical Data Supporting TAMP Therapy Platform at SIO 2026 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2608736296","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608736296?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:30","pubTimestamp":1770211841,"startTime":"0","endTime":"0","summary":"RenovoRx Inc. has announced that new clinical data supporting its TAMP Therapy Platform will be presented at the 2026 Society of Interventional Oncology  Annual Scientific Meeting on February 6, 2026. The study, titled \"Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro-Perfusion to Optimize Drug Delivery in Solid Tumors,\" explores a method for measuring intra-arterial pressure during procedures using the RenovoCath, an adjustable, double-balloon drug-delivery device. The findings show that a simplified, external pressure transducer provides reliable intra-arterial pressure measurements during TAMP procedures, with results indicating that procedural variables such as catheter balloon spacing and vessel diameter can influence peak intra-arterial pressure. The clinical data have not yet been presented and will be shared during the SIO 2026 meeting.Disclaimer: This news brief was created by Public Technologies  using generative artif","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL8h1Gfw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","IE00B3QW5Z07.USD","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014005.SGD","BK4585","LU2210149790.SGD","RNXT","LU2095319765.USD","NDAQ","IE00BGHQF748.EUR","SG9999014021.USD","BK4588","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014039.USD","BK4112","LU0314104364.USD"],"gpt_icon":0},{"id":"2608629873","title":"RenovoRx Announces Clinical Data Supporting the Tamp™ Therapy Platform Will Be Presented at the Sio 2026 Annual Scientific Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2608629873","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608629873?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:30","pubTimestamp":1770211802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nTUA6QWQ8F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","RNXT","BK4139"],"gpt_icon":0},{"id":"2608281559","title":"RenovoRx Inc. details RenovoCath commercialization progress and pipeline developments in new investor presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2608281559","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608281559?lang=en_us&edition=fundamental","pubTime":"2026-02-03 06:31","pubTimestamp":1770071505,"startTime":"0","endTime":"0","summary":"RenovoRx Inc. provided an update on its recent commercialization efforts and clinical progress. The company reported approximately $900,000 in revenue through the third quarter of 2025 following the initiation of commercial activities for its FDA-cleared RenovoCath device. As of January 2026, the number of cancer center customers approved to purchase RenovoCath increased from 5 to 14, with 9 active commercial users and additional centers in the approval process. RenovoRx estimates an initial potential peak annual U.S. revenue opportunity of approximately $400 million for RenovoCath as a stand-alone device, with potential for further expansion in future applications. The company continues to develop combination therapies based on its proprietary Trans-Arterial Micro-Perfusion  platform, including a lead drug-device candidate, Intra-Arterial Gemcitabine , which has received FDA Orphan Drug Designation for pancreatic and bile duct cancers. RenovoRx is advancing its pivotal Phase III TIGeR","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL8nyzsr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","RNXT"],"gpt_icon":0},{"id":"2606711013","title":"RenovoRx Reports $900,000 in RenovoCath Sales for First Nine Months of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2606711013","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606711013?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:31","pubTimestamp":1769607101,"startTime":"0","endTime":"0","summary":"RenovoRx Inc. reported that it is in the early stages of commercializing its FDA-cleared RenovoCath device. In December 2024, the company received its first commercial purchase orders for RenovoCath. For the first nine months of 2025, RenovoRx generated approximately $900,000 in revenue from RenovoCath sales. Several customers have placed repeat orders, and the company is expanding its customer base to include more medical institutions, such as high-volume National Cancer Institute-designated centers. RenovoRx stated it will continue to explore additional revenue-generating activities, either independently or with a commercial partner.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to g","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL3fJp3t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014013.SGD","LU2210150020.SGD","BK4585","LU0314104364.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014021.USD","LU2210149790.SGD","NDAQ","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4539","BK4588","SG9999014039.USD","RNXT","BK4112","SG9999014005.SGD","BK4139"],"gpt_icon":0},{"id":"2606711082","title":"RenovoRx to Present New Clinical Data on Pressure-Guided Chemotherapy Delivery at SIO 2026 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2606711082","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606711082?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:30","pubTimestamp":1769607031,"startTime":"0","endTime":"0","summary":"RenovoRx Inc. has announced that its abstract titled \"Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro Perfusion to Optimize Drug Delivery in Solid Tumors\" has been accepted for presentation at the 2026 Society of Interventional Oncology  Annual Scientific Meeting. The presentation is scheduled for February 6, 2026, in Savannah, Georgia. The study evaluates a method for real-time intra-arterial pressure monitoring during TAMP  procedures using the RenovoCath double-balloon drug-delivery device. The results will be presented at the SIO 2026 meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via Glo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL54WCfp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BKPKM429.USD","LU2210149790.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","RNXT","IE00B3QW5Z07.USD","SG9999014021.USD","LU2095319765.USD","SG9999014005.SGD","BK4585","SG9999014013.SGD","BK4139","BK4112","BK4539","LU2210150020.SGD","LU0314104364.USD","BK4588","SG9999014039.USD"],"gpt_icon":0},{"id":"2605766493","title":"RenovoRx Chief Medical Officer Ramtin Agah Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605766493","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605766493?lang=en_us&edition=fundamental","pubTime":"2026-01-22 20:00","pubTimestamp":1769083258,"startTime":"0","endTime":"0","summary":"Ramtin Agah, Chief Medical Officer of RenovoRx Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL6CqkC8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RenovoRx Chief Medical Officer Ramtin Agah Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT","BK4139","BK4539"],"gpt_icon":0},{"id":"2604013275","title":"RenovoRx Inc. unveils investor presentation highlighting RenovoCath commercialization and clinical progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2604013275","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604013275?lang=en_us&edition=fundamental","pubTime":"2026-01-20 00:50","pubTimestamp":1768841409,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief on January 19, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nNDL8HMCLc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNXT","BK4539"],"gpt_icon":0},{"id":"2603619604","title":"RenovoRx CEO to Present at AlphaNorth Capital Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2603619604","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603619604?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:30","pubTimestamp":1768397417,"startTime":"0","endTime":"0","summary":"RenovoRx Inc. will participate in the AlphaNorth Capital Event from January 16-18, 2026, at the Grand Hyatt Baha Mar in Nassau, Bahamas. CEO Shaun Bagai is scheduled to discuss the company's commercial and clinical program progress, including developments with the RenovoCath device and updates on ongoing clinical trials.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via GlobeNewswire  on January 14, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDLWknm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014021.USD","SG9999014013.SGD","RNXT","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4539","LU2210150020.SGD","LU0314104364.USD","BK4588","IE00BGHQF748.EUR","LU2095319765.USD","BK4112","BK4585","IE00BKPKM429.USD","SG9999014005.SGD","NDAQ","BK4139","SG9999014039.USD"],"gpt_icon":0},{"id":"2601362181","title":"RenovoRx Unveils Promising Phase III Data on TAMP Platform for Pancreatic Cancer at ASCO GI 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601362181","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601362181?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:30","pubTimestamp":1767879011,"startTime":"0","endTime":"0","summary":"RenovoRx Inc. has announced that new clinical data from a pharmacokinetic  and pharmacodynamic sub-study of its ongoing Phase III TIGeR-PaC clinical trial will be presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2026 . The abstract, led by Dr. Paula M. Novelli of the University of Pittsburgh Medical Center, reports results from a study comparing intra-arterial gemcitabine  delivered via the Trans-Arterial Micro-Perfusion  therapy platform with standard intravenous gemcitabine in patients with locally advanced pancreatic cancer. The study analyzed systemic drug exposure and peak plasma concentrations in 16 patients across six clinical sites.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL6xRBFs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","LU0314104364.USD","SG9999014005.SGD","SG9999014013.SGD","IE00B64PRP62.GBP","BK4585","LU2095319765.USD","BK4539","IE00BGHQF748.EUR","RNXT","IE00BKPKM429.USD","BK4139","IE00B3QW5Z07.USD","BK4588","NDAQ","BK4112","SG9999014021.USD","LU2210149790.SGD","SG9999014039.USD"],"gpt_icon":0},{"id":"2601588577","title":"RenovoRx Chief Medical Officer Ramtin Agah Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601588577","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601588577?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614447,"startTime":"0","endTime":"0","summary":"Ramtin Agah, Chief Medical Officer and Director of RenovoRx Inc., has reported the acquisition of common shares of RenovoRx Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL3sb70c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"RenovoRx Chief Medical Officer Ramtin Agah Reports Acquisition of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT","BK4139","BK4539"],"gpt_icon":0},{"id":"2600109371","title":"RenovoRx Chief Medical Officer Ramtin Agah Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2600109371","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600109371?lang=en_us&edition=fundamental","pubTime":"2026-01-03 06:01","pubTimestamp":1767391311,"startTime":"0","endTime":"0","summary":"Ramtin Agah, Chief Medical Officer and Director of RenovoRx Inc., has reported the acquisition of common shares of RenovoRx Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDLbfYBxm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"RenovoRx Chief Medical Officer Ramtin Agah Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT","BK4139","BK4539"],"gpt_icon":0},{"id":"2600980830","title":"RenovoRx Faces Nasdaq Delisting Risk Over Minimum Bid Price Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2600980830","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600980830?lang=en_us&edition=fundamental","pubTime":"2026-01-03 05:11","pubTimestamp":1767388280,"startTime":"0","endTime":"0","summary":"RenovoRx Inc. has received a deficiency notice from the Nasdaq Stock Market for failing to maintain the minimum $1.00 bid price required for continued listing on the Nasdaq Capital Market. The company's stock traded below this threshold for 32 consecutive business days, prompting the notice. RenovoRx has until June 30, 2026, to regain compliance by achieving a closing bid price of at least $1.00 per share for ten consecutive business days. If the company does not meet this requirement, it may be eligible for an additional 180-day compliance period, provided it meets other listing standards and notifies Nasdaq of its intentions to cure the deficiency, potentially through a reverse stock split. Failure to comply could result in delisting, though the company would have the right to appeal. The notice does not have an immediate effect on the company’s stock listing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDL53HSlL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RNXT","BK4139"],"gpt_icon":0},{"id":"2593248409","title":"RenovoRx CEO Shaun Bagai Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593248409","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593248409?lang=en_us&edition=fundamental","pubTime":"2025-12-22 20:01","pubTimestamp":1766404863,"startTime":"0","endTime":"0","summary":"Shaun Bagai, Chief Executive Officer of RenovoRx Inc., reported an acquisition of common shares of RenovoRx Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 22, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL7DpPvn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RenovoRx CEO Shaun Bagai Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT","BK4139","BK4539"],"gpt_icon":0},{"id":"2592169400","title":"RenovoRx CEO Shaun Bagai Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592169400","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592169400?lang=en_us&edition=fundamental","pubTime":"2025-12-19 20:01","pubTimestamp":1766145661,"startTime":"0","endTime":"0","summary":"Shaun Bagai, Chief Executive Officer of RenovoRx Inc., reported the acquisition of common shares of RenovoRx Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDLRXrXc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RenovoRx CEO Shaun Bagai Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNXT","BK4539"],"gpt_icon":0},{"id":"2592928879","title":"RenovoRx Chief Medical Officer Ramtin Agah Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592928879","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592928879?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:00","pubTimestamp":1765972855,"startTime":"0","endTime":"0","summary":"Ramtin Agah, Chief Medical Officer and director of RenovoRx Inc., has reported the acquisition of common shares of RenovoRx Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL9j0m1r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RenovoRx Chief Medical Officer Ramtin Agah Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","RNXT"],"gpt_icon":0},{"id":"2590951950","title":"RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590951950","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590951950?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:30","pubTimestamp":1765459800,"startTime":"0","endTime":"0","summary":"The Accepted Abstract Provides Supportive Evidence for the TAMP Therapy Platform’s Novel, Localized Approach to Targeted Chemotherapeutic Delivery via Additional Pharmacokinetic and Pharmacodynamic Da","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3203909/0/en/RenovoRx-Announces-Acceptance-of-Clinical-Data-Abstract-at-the-ASCO-Gastrointestinal-Cancers-Symposium-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT","IAG","BK4539","BK4017","BK4139"],"gpt_icon":0},{"id":"2589337720","title":"RenovoRx Chief Medical Officer Ramtin Agah Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2589337720","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589337720?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:01","pubTimestamp":1765195262,"startTime":"0","endTime":"0","summary":"Ramtin Agah, Chief Medical Officer and Director of RenovoRx Inc., has reported the acquisition of common shares of RenovoRx Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL1Ssp0B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RenovoRx Chief Medical Officer Ramtin Agah Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNXT","BK4539"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.renovorx.com","stockEarnings":[{"period":"1week","weight":-0.0095},{"period":"1month","weight":-0.0677},{"period":"3month","weight":-0.011},{"period":"6month","weight":-0.1659},{"period":"1year","weight":-0.3618},{"period":"ytd","weight":0.1319}],"compareEarnings":[{"period":"1week","weight":-0.0237},{"period":"1month","weight":-0.0205},{"period":"3month","weight":0.0099},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1215},{"period":"ytd","weight":-0.0063}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.049533},{"month":2,"riseRate":0.6,"avgChangeRate":0.115265},{"month":3,"riseRate":0,"avgChangeRate":-0.152336},{"month":4,"riseRate":0,"avgChangeRate":-0.164804},{"month":5,"riseRate":0.5,"avgChangeRate":0.046228},{"month":6,"riseRate":0.5,"avgChangeRate":0.03467},{"month":7,"riseRate":0.25,"avgChangeRate":-0.034228},{"month":8,"riseRate":0.25,"avgChangeRate":-0.119414},{"month":9,"riseRate":0.4,"avgChangeRate":-0.050074},{"month":10,"riseRate":0,"avgChangeRate":-0.120676},{"month":11,"riseRate":0.6,"avgChangeRate":0.028303},{"month":12,"riseRate":0.6,"avgChangeRate":0.479671}],"exchange":"NASDAQ","name":"RenovoRx Inc","nameEN":"RenovoRx Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest RenovoRx Inc(RNXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"RenovoRx Inc,RNXT,RenovoRx Inc股票,RenovoRx Inc股票老虎,RenovoRx Inc股票老虎国际,RenovoRx Inc行情,RenovoRx Inc股票行情,RenovoRx Inc股价,RenovoRx Inc股市,RenovoRx Inc股票价格,RenovoRx Inc股票交易,RenovoRx Inc股票购买,RenovoRx Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest RenovoRx Inc(RNXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}